• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·0KHE.L
Held by 2 Gurus
Share

Revvity, Inc. Stocks

$ 124.09Last Updated 11.09.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

$ 13.61B

$ 124.09
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.02%

Fund

CITADEL ADVISORS LLC

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

Bridgewater Associates

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.02%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%-0.00%

Latest news

13.01.2026 15:40

New York morning: focus on inflation and the start of the reporting season

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Revvity, Inc., originally established in 1937 and headquartered in Waltham, Massachusetts, operated as PerkinElmer, Inc. until its rebranding in April 2023. This global company is a key provider of diverse products, services, and specialized solutions across the diagnostics, life sciences, and applied services sectors. Its operations are divided into two primary segments: 1. Discovery & Analytical Solutions: This segment furnishes a comprehensive array of tools, including instruments, reagents, informatics platforms, software, subscription services, and advanced detection and imaging technologies. These offerings are designed to empower scientists in accelerating research discoveries within the life sciences. Beyond direct product sales, this segment also delivers contract research and laboratory services. Furthermore, it offers analytical solutions and services to assess environmental health, specifically concerning air, water, and soil quality. It also caters to the agricultural sector with solutions for farmers and food producers and provides specialized analytical instrumentation for diverse industrial applications such as the chemical, semiconductor, electronics, energy, lubricant, petrochemical, and polymer industries. 2. Diagnostics: This segment focuses on providing instruments, reagents, assay platforms, and software products critical for the early identification of genetic disorders, particularly during pregnancy and early childhood, as well as for infectious disease screening. Its diagnostic tools are employed in the screening and testing for a range of genetic abnormalities and conditions, including Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic disorders. This segment is also involved in developing advanced technologies that facilitate genomic workflows, utilizing techniques like protein-coupled receptor analysis and next-generation DNA sequencing, with applications spanning oncology, immunodiagnostics, and drug discovery. Revvity serves a broad clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health organizations, private healthcare providers, medical professionals, and governmental bodies.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of RVTY is 122 and suggests 1.61% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.09.2026 02:19

"Dario Is Right": Musk and Altman Backed Anthropic CEO's Call to Slow Down AI Development

13.09.2026 00:58

Data from some Revolut customers was leaked

12.09.2026 16:01

Small caps last week: Chewy's earnings miss, Signet's best day ever, AE rethinks ads

12.09.2026 13:01

The iPhone Reboot, the AGI Era, and Silicon Valley's Right Turn

12.09.2026 05:06

Spam from OpenAI's AI agents disrupted the developer service for four days

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026